Background: Hypothyroidism is a known consequence of external beam radiotherapy to the neck encompassing part or whole of the thyroid gland for over 40 years. Still thyroid function tests are not a part of routine follow up of head -neck cancer patients treated with radiotherapy with or without surgery and / or chemotherapy.
INTRODUCTION
varies from 5 to 10% [6, 7] and that of sub-clinical hypothyroidism (elevated serum Thyroid StimuCarcinoma of the head & neck region is the 5 th lating Hormone level and normal serum Thyroxin most common malignancy worldwide [1] and comlevel) is about 6% [8] in other series. Addition of monest malignancy among Indian males, as per surgery to the neck region vastly increases the ICMR reports, probably due to increased use of incidence of hypothyroidism but addition of chewing tobacco and smoking. External beam chemotherapy probably has little or no effect. [9] radiation is an integral part of management of such malignancies, used either alone (in early Though hypothyroidism has a significant impact stage tumors) or in combination with surgery and on the quality of life, assessment of thyroid func / or chemotherapy (in advanced stages). Target  tion is not yet a part of routine follow up of head volume of irradiation usually includes part or and neck cancer patients, even in long term sur whole of the thyroid gland. Though adult thyvivors. roid cells are relatively radio-resistant due to their low proliferative index [2] , hypo-function of the thyIn this ongoing non randomized prospective roid gland is a known side effect of radiotherapy study we have tried to assess to the head and neck malignancies for more than 1. Risk of developing hypothyroidism in our pa 40 years [3] . After external beam radiotherapy to tients with head & neck malignancies, where the neck, the documented incidence of hypothyradiation portals included whole or most of roidism varies widely, from 03 % [4] to 44 %. [5] the thyroid gland. When sub-divided, incidence of clinical hypothy-2. Whether addition of chemotherapy has any roidism (elevated serum Thyroid Stimulating Horadditional effect on developing hypothy mone level and depressed serum Thyroxin level) roidism in these patients.
MATERIALS AND METHODS

Patients
From September 2001 to November 2003, 187 patients with histologically proved head & neck malignancy of epithelial origin, who were destined to receive external beam radio therapy to the primary site as well as to the neck, and whose radiation target volume will include whole or most of the thyroid gland, were included in a prospective non randomized study in the department of Radiotherapy of Nilratan Ratan Sircar Medical College & Hospital, Kolkota. The patients may or may not receive neo-adjuvant or con current chemotherapy as part of their management and the decision was left in the hand of the concerned radiation oncologists. Patients having T4 tumors or N3 neck nodes or distal metastasis at presentation were not included in the study because of their expected short survival and possi ble invasion of the thyroid gland itself (in case of T4 tumors of the larynx). Similarly patients having one or more nod ules in the thyroid gland as well as those who underwent laryngectomy before irradiation (thyroid lobectomy is of ten a part of laryngectomy operation) were also excluded from the study, though they may be euthyroid at presenta tion. Similarly patients who underwent laryngectomy after irradiation due to uncontrolled tumour were also excluded from the result analysis.
Patient characteristics are shown in Table 1 .
Treatment
Of the 187 patients, 93 (49.7 %) were planned to receive radiotherapy alone, 71 (38 %) to receive neo-adjuvant chemotherapy with Cisplatin & 5 FU and the rest 23 (12.3%) patients to receive concurrent chemo-radiation. In neo adjuvant setting, Cisplatin was given in a dose of 50 mg / sq. meter per day on days 1 & 2 and 5-FU 600 mg / sq. meter per day by short infusion on days 1,2 & 3. The cycle was repeated at 21 days interval for 3-4 cycles to be followed by external beam radiotherapy. In concurrent setting, Cisplatin 20 mg / sq. meter and 5-FU 300 mg / sq. meter were given weekly for five weeks along with radiotherapy, preferably on Fridays to give rest to the patients on weekends for re covery. All patients with or without completion of the pro posed neo-adjuvant chemotherapy course, were treated with radiotherapy to the primary site as well as to the neck nodes covering the entire or most of the thyroid gland. Pro posed dose of radiotherapy was 6000 -6600 cGy in 30 to 33 fractions over a period of 40 to 45 days and was delivered by parallel opposing lateral beams with appropriate wedges with Tele-cobalt machine.
Investigations
Before initiation of treatment, all patients underwent 1. Detailed history taking and physical examination, in cluding thyroid gland 2. Complete blood count 3. Kidney function tests 4. Liver function tests 5. X-ray chest 6. CT scan of the primary site and the neck, whenever possible 7. Thyroid function tests.
Treatment started only when the blood examination reports were within normal limits. Thyroid function tests were done by chemiluminescence technique and the accepted normal values were T3: 60.0 -181.0 ng / dl; T4: 4.5 -12.6 µg / dl; and TSH: 0.35 -5.50 µIU /ml.
We were not able to organize tests for antibodies against either thyroperoxidase or thyroglobulin where a positive result could indicate thyroiditis.
Detailed history and physical examinations with particular emphasis to those of hypothyroidism, were done in every follow up visit and thyroid function tests were repeated at six weeks after completion of radiation and thereafter at six months interval.
RESULTS
Of the 187 patients, entered in the study, five were excluded after the first thyroid function tests as two of them had clinical and three sub-clinical hypothyroidism and primary goal of our study was to know the effect of radiation on normal thyroid functions and whether effect can be modi fied by chemotherapy or not. 182 patients were available for the study, of whom 91 patients received radiotherapy only, 68 received neo-adjuvant chemotherapy and the rest 23 patients received concurrent chemo-radiation.
Of the 68 patients selected to receive neo-adjuvant chemo therapy, 41 patients completed the proposed four cycles, 23 completed three cycles and the rest four patients dis continued after two cycles, mostly due to hematological toxicities and to some extent due to their unwillingness to continue further.
Of the 23 patients planned to receive concurrent chemo radiation, 14 completed the five cycles and in the rest chemo therapy was discontinued after three or four cycles mainly due to acute mucosal toxicities.
What ever be the number cycles of chemotherapy the pa tients have received, all of them have received external beam radiotherapy. 55 patients received 6600 cGy, 82 received 6000 cGy, 21 discontinued between 5000 -6000 cGy and the rest discontinued in between 4000 to 5000 cGy.
All the selected patents were euthyroid at beginning of therapy but the incidence of hypothyroidism increased with the passage of time. The results have been shown in [ Table  2 ]. The time period was calculated from the date of comple tion of radiotherapy. Of the patients with uncontrolled dis ease post irradiation, four underwent laryngectomy and therefore they were excluded from the analysis, leaving behind 178 patients.
DISCUSSION
Besides surgical intervention, radiotherapy is the only known curative management for the patients with head and neck malignancies. It may be used either alone or in combination with surgery and/or radiotherapy. In 1961, Felix et al [3] first reported a case of hypothyroidism six years af ter treatment with external radiotherapy, in a patient of laryngeal carcinoma. Since then, several other investigators have reported the occurrence of hypothyroidism in patients who have received radiotherapy in the neck region. Despite these reports, tests for thyroid functions are not yet in cluded in the follow up protocols of patients with head and neck malignancies. [10] Estimation of the magnitude of the problem is very diffi cult and confusing because of the fact that some series have included patients treated with radiotherapy alone, [11, 12] while Table 2 : Incidence of hypothyroidism with passage of time others have included patients that had hemi-thyroidectomy as a part of laryngectomy, in addition to pre-or post-opera tive radiotherapy. [13, 5, 14] In their study, with a median follow up of 4.4 years, Mercado et al [15] reported 48 % and 67 % Kaplan -Meier projected incidence of hypothyroidism at 5 and 8 years respectively, when patients with head and neck malignancies were treated with external beam radiotherapy with or without concurrent chemotherapy. The median time to the devel opment of hypothyroidism was 1.4 years. Turner et al [12] reported 14.3% incidence of clinical and 23.8% sub-clinical hypothyroidism following radiotherapy to the whole of the thyroid gland. They estimated that by 5 years up to 40% of the patients may become hypothyroid. Their estimated in cidence of hypothyroidism at 5 years is almost similar to that of Marcado et al but Tell et al [16] reported a much lower incidence. They treated 264 patients with head and neck malignancies by external beam radiotherapy and at a me dian follow up of 19 months, 6 % patients developed clini cal and 22 % sub-clinical hypothyroidism. Median time to develop hypothyroidism was 15 months. In their series, in cidence of sub-clinical hypothyroidism was significantly higher when whole of the thyroid gland was included in the target volume compared to patients where only part of the thyroid gland was irradiated.
There is a general agreement that hypothyroidism is a much more common complication following combined surgical and radio-therapeutic management of head and neck cancers with a frequency ranging in literature from 43 to 66 % of ten depending upon the duration of follow up [5, 9, 14] . On the other hand, some researchers have claimed that hypothy roidism is a rare or nonexistent complication of radiotherapy alone to the neck. [17, 14] At 2 years, overall incidence of clinical hypothyroidism of our reported patients was 17.8% and of sub-clinical hypothy roidism was 21.8%. Due to diversity of reported incidences, type of managements and duration of follow up in published series, it is almost impossible to compare our results with others. Again as it is a late effect, it is expected that with the passage of time the incidence will increase and some of the patients with sub-clinical hypothyroidism will progress to clinical one. In this report, our maximum follow up is two years only.
Dose of radiation required to produce hypothyroidism is also confusing. DeGroot [18] and Hancock et al [19] suggested that radiation doses in the range of 3000 to 8000 rads are re quired to produce hypothyroidism. At the same time Hancock et al [20] reviewed 1787 patients of Hodgkin's dis ease treated with Mantle field irradiation in the dose of 3500 -4500 cGy and estimated a 43% actuarial risk of develop ing hypothyroidism at 20 years.
Still very few studies have described the effect of chemo therapy on thyroid gland. Bajorunas [21] mentioned L-aspara ginase as an agent that may depress thyroid function. It is expected that chemotherapy, particularly concurrent chemo therapy will sensitize the thyroid gland to radiation and will increase the incidence of hypothyroidism. But Posner et al, [9] Weissler et al [22] and Sinrad et al [23] found no effect of combination chemotherapy on thyroid gland in patients with head and neck malignancies. In our patients also we have not found any significant effect of chemotherapy, whether neo-adjuvant or concurrent, on thyroid gland, though both clinical and sub-clinical hypothyroidisms were a bit more common in the concurrent group. But as the number of patients was very small in that group, the inci dence has failed to reach a clinically significant level.
How radiotherapy produces hypothyroidism is also incom pletely understood. This may be due to direct follicular de struction or prevention of cell division or vascular damage to the thyroid gland or immunologically mediated damage to the thyroid gland or a various combination of the fac tors. Histological examination of the thyroid gland after external irradiation has documented follicular cell damage and vascular damage following doses as low as 225 cGy. [12] An immunologic influence has been suggested by Einhorn & Wikholm. [24] Because adult thyroid cells in vivo are not expected to have a high turnover rate and are well differ entiated, it has been postulated that they may undergo radiation induced apoptosis, varying between different patients.
Most of the common signs & symptoms of hypothyroidism e.g. depression, lethargy, skin changes, constipation, weight gain (> 10% of original body weight) etc are ill defined and can be easily overlooked in cancer patients. Because there is a high rate of co-morbidity in them and the disease and its' treatment may have nutritional, physical and psycho logical consequences in these patients, that may easily mask the clinical features of hypothyroidism. For these reasons, clinical examination of the cancer patients for features of hypothyroidism is not a reliable one.
We have found no effect of age, sex, primary site, neck node status or radiation dose on the incidence of hypothyroidism. Similar were the findings of Mercado [15] and Tell. • Published quartly in last weeks of March, June, September and December.
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